Survey
Two Week Delay: Survey on Post-Bariatric Hypoglycemia (PBH) and Avextitide July 2025
Ticker(s): AMLXThe survey results include 30 expert physicians that treat patients with Post-Bariatric Hypoglycemia (PBH).
How many patients do you currently manage with Post-Bariatric Hypoglycemia (PBH?)
How many patients do you manage for PBH with diet modification?
How many patients do you manage for PBH with pharmacotherapy (acarbose, others)
How would you best describe your specialty?
- Endocrinologist:
- Other; Please Specify
- Gastroenterologist:
- Bariatric surgeon:
What do you believe to be the approximate US prevalence of symptomatic PBH patients
despite treatment.
What percentage of your symptomatic PBH patients are inadequately managed with diet
modification and/or pharmacotherapy (acarbose, others)?
What percentage of your symptomatic PBH patients have you attempted to manage with pharmacotherapy (acarbose, others)?
What percentage of your symptomatic PBH patients are adequately managed with pharmacotherapy (acarbose, others)?
If Avexitide demonstrates a ≥50% placebo-adjusted reduction in composite Level 2/3
hypoglycemia in the Phase 3 LUCIDITY trial over 24 weeks, what percentage of your symptomatic PBH patients who are inadequately managed with diet modification and/or
pharmacotherapy (acarbose, others) would you prescribe it to?
If Avexitide demonstrates a ≥30% placebo-adjusted reduction in composite Level 2/3
hypoglycemia in the Phase 3 LUCIDITY trial over 24 weeks, what percentage of your
symptomatic PBH patients who are inadequately managed with diet modification and/or
pharmacotherapy (acarbose, others) would you prescribe it to?
What do you believe the probability of success (%) is for the Phase 3 LUCIDITY trial on the
primary endpoint of composite Level 2/3 hypoglycemia reduction compared to placebo?
If Avexitide is approved in PBH, what percentage of your patients currently managed with diet modification would switch to Avexitide?
If Avexitide is approved in PBH, what percentage of your patients currently managed with pharmacotherapy (acarbose, others) would switch to Avexitide?
If Avexitide is approved in PBH, how excited (1 [low]-10 [high]) will you be to prescribe it for your patients and why?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
